Refine by
Diabetes Articles & Analysis
483 news found
Researchers have long recognized the importance of CCM in regulating cellular function and contributing to the understanding of various diseases, including cancer, diabetes, and neurodegenerative disorders. However, traditional methods of analyzing these complex metabolic networks have often fallen short, hindering progress in the field. ...
While primarily less soluble, Tirzepatide’s molecular complexity does not impede its significance in the study of type 2 diabetes and beyond. By facilitating explorations into multifaceted metabolic pathways, Tirzepatide enriches insights into dual receptor interactions that inspire the development of next-generation research models. ...
His research explored metabolic imbalances linked to Type 2 Diabetes, and he previously worked as a Research Engineer, focusing on NMR-based metabolic characterisation and magnetic homogeneity ...
Ace Therapeutics launches its cutting-edge in vivo models of diabetes mellitus. These models—chemically induced, genetically engineered, or diet-induced—have the potential to advance diabetes research by giving scientists the means to support the identification and development of novel treatment approaches. ...
Such fat accumulation can have serious health consequences, raising the risk of chronic diseases like cardiovascular conditions, diabetes, and some cancers. It is usually associated with a higher prevalence of non-alcoholic fatty liver disease (NAFLD) and asthma. ...
Some of the anti-tumor APIs supplied by Protheragen-ING are: enzalutamide, olaparib, idelalisib, neratinib maleate, ixazomib citrate, bendamustine hydrochloride monohydrate, ponatinib HCL, dasatinib, lenalidomide, afatinib dimaleate, etc. Dedicated Solutions for Diabetes Management For diabetes, Protheragen-ING’s hypoglycemic APIs are the key to its cure. ...
Ace Therapeutics, a leading provider of preclinical research services and products, is proud to announce the launch of its extensive suite of diabetic mouse models. These models have been specifically designed to enable research on different types of diabetes including type 1, type 2, and gestational diabetes, providing valuable insights into ...
This novel glucagon-like peptide-1 (GLP-1) receptor agonist has generated significant excitement within the pharmaceutical and life sciences industries due to its remarkable efficacy in managing type 2 diabetes. Semaglutide represents a paradigm shift in the treatment of type 2 diabetes, as it targets the root causes of the disease rather than solely focusing ...
Semaglutide Side Chain serves as a pivotal component in the synthesis of semaglutide, an innovative medication utilized in the treatment of type 2 diabetes. Huateng Pharma's unwavering dedication to excellence and innovation shines through in the meticulous development and production of these essential compounds, ensuring the highest standards of quality and purity. ...
This finding holds great promise for individuals living with diabetes, as it eliminates the need for frequent injections. In another study published in the Journal of Drug Delivery Science and Technology, researchers investigated and revealed that the coated microneedles were able to efficiently deliver the vaccine, eliciting a robust immune response in animal models. ...
CD BioSciences, a US-based CRO serving the global life science research community, has announced the launch of its new services to study the Mechanistic Target of Rapamycin (mTOR) in diabetes and metabolism research. The mechanistic Target of Rapamycin is a serine/threonine protein kinase that is inhibited by rapamycin, a bacterial compound originally isolated from Easter Island ...
We are delighted to welcome Roczen to the community of healthcare organisations leveraging Vantage Software! We look forward to working together and helping them deliver exceptional care and support to those living with chronic conditions. Book a Free Demo ...
Huateng Pharma proudly announces the launch of a groundbreaking suite of anti-diabetes intermediates, featuring key compounds such as Canagliflozin, Dapagliflozin, Empagliflozin, and Semaglutide. Emphasizing the potential impact on diabetes drug development, Huateng Pharma's Research and Development Director expressed enthusiasm, stating, "Our new line of ...
Data from pivotal PHOTON trial demonstrate long term efficacy of aflibercept 8 mg with extended intervals comparable to Eylea (aflibercept 2 mg) at fixed 8-weekly dosing over two years Patients assigned to a 16-week dosing regimen at baseline received a mean of 7.8 injections (6 fewer than Eylea) Safety profile of aflibercept 8 mg in diabetic macular edema (DME) remains ...
ByBayer AG
“Despite progress in risk reduction in type 2 diabetes, chronic kidney disease in type 1 diabetes remains understudied, leaving a huge unmet need to reduce the risks of end-stage kidney disease and cardiovascular events. ...
ByBayer AG
It provides customers with comprehensive solutions including instruments, consumables, reagents, and software for the analysis of gene loci related to birth defect prevention and control, drug genomes, tumours, infectious diseases, and other fields.GETOTEC, a fully-automated capillary electrophoresis instrument, ClinCap 1000, with independent intellectual property rights under FPI Life Sciences, ...
Global phase III QUASAR study will assess the efficacy and safety of aflibercept 8 mg in macular edema secondary to retinal vein occlusion (RVO) Study comes after positive data from the phase III PULSAR trial in neovascular (wet) age-related macular degeneration (nAMD) and phase II/III PHOTON trial in diabetic macular edema (DME) QUASAR is expected to enroll around 800 ...
ByBayer AG
Epalrestat Epalrestat is used to treat diabetic neuropathy, a condition that affects millions of people worldwide. By providing high-quality epalrestat as active pharmaceutical ingredients, Alfa Chemistry is supporting the development of better treatments for this condition and helping to improve the quality of life for people living with diabetes. ...
There are also contraindications to fractional laser, severe diabetics, hypertension, pregnancy, breastfeeding and those allergic to light are not allowed to do the treatment. ...
Aflibercept 8 mg was investigated in neovascular (wet) age-related macular degeneration (PULSAR) and diabetic macular edema (PHOTON) to evaluate efficacy and safety compared to Eylea (aflibercept 2 mg). ...
ByBayer AG